

# POWERING THE FUTURE OF TARGETED ALPHA THERAPIES

**TAG1 IS BUILDING A MORE RELIABLE AND SCALABLE ISOTOPE SUPPLY CHAIN TO MEET THE NEEDS OF RADIOLIGAND THERAPY INNOVATORS WORLDWIDE.**

TAG1 Inc. is a radiopharmaceutical company dedicated to strengthening the global supply chain for Targeted Alpha Therapies (TATs). Through our proprietary Targeted Alpha Generator (TAG1) platform, we enable decentralized, high-purity production of Lead-212, empowering research institutions, hospitals, and radiopharmacies to drive the next generation of precision cancer therapies.

## TAG1'S INFRASTRUCTURE BEHIND ALPHA INNOVATION



### PROPRIETARY TAG1 GENERATOR

On-demand  
production of Lead-212,  
built for scalability



### DECENTRALIZED SUPPLY MODEL

Designed for  
radiopharmacies  
and hospitals  
worldwide



### STRATEGIC PARTNERSHIPS

Including NRG  
PALLAS for  
irradiation and  
source material



### PATIENT-FOCUSED PURPOSE

Enabling timely  
access to life-saving  
targeted therapies

## BUILT BY RADIOPHARMA EXPERTS

TAG1 has recently added board members from POINT Biopharma, University of Missouri and Precirix. TAG1 has also entered into a strategic production partnership with NRG PALLAS.

### LET'S CONNECT.

TAG1 Inc. 16091 Swingley Ridge Road, Suite 360, Chesterfield, MO 63017 | [info@tag1inc.com](mailto:info@tag1inc.com)  
[www.tag1inc.com](http://www.tag1inc.com) | (314) 439-1141



# RETHINKING HOW THERAPEUTIC ISOTOPES REACH PATIENTS

**TAG1 IS POSITIONED TO BE A LEADING PB-212 GENERATOR PRODUCER IN THE U.S. FOR RADIOPHARMACY AND HOSPITAL NETWORKS.**

## DIFFERENTIATED TECHNOLOGY

Patented generator design with lasting advantages and deep radionuclide expertise.

## STRATEGIC MARKET POSITION

First-to-US market with strong interest from biotech and pharma companies.

## HIGH MARKET DEMAND

Strong and growing demand driven by critical unmet needs in targeted radiotherapy.

## SCALABLE & SUSTAINABLE GROWTH


Low CAPEX, reduced production costs, and a growing Lead-212 supply ecosystem.

## REDEFINING ACCESS TO LEAD-212

Lead-212 (Pb-212) is a powerful alpha-emitting isotope with the potential to treat a range of solid tumors with precision and potency. Yet access to this isotope has been limited by supply challenges. TAG1 is solving this problem through scalable, consistent production technology that meets both clinical and commercial needs.



**CENTRALIZED**



**DECENTRALIZED**



**GENERATOR MODEL**

### LET'S CONNECT.

